PMID- 30929389
OWN - NLM
STAT- MEDLINE
DCOM- 20190410
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 40
IP  - 3
DP  - 2019 Mar 14
TI  - [Clinical implications and prognostic value of TP53 gene mutation and deletion in 
      patients with myelodysplastic syndromes].
PG  - 215-221
LID - 10.3760/cma.j.issn.0253-2727.2019.03.010 [doi]
AB  - Objective: To explore the clinical implications and prognostic value of TP53 gene 
      mutation and deletion in patients with myelodysplastic syndromes (MDS) . Methods: 
      112-gene targeted sequencing and interphase fluorescence in situ hybridization 
      (FISH) were used to detect TP53 mutation and deletion in 584 patients with newly 
      diagnosed primary MDS who were admitted from October 2009 to December 2017. The 
      association of TP53 mutation and deletion with several clinical features and 
      their prognostic significance were analyzed. Results: Alterations in TP53 were 
      found in 42 (7.2%) cases. Of these, 31 (5.3%) cases showed TP53 mutation only, 8 
      (1.4%) cases in TP53 deletion only, 3 (0.5%) cases harboring both mutation and 
      deletion. A total of 37 mutations were detected in 34 patients, most of them 
      (94.6%) were located in the DNA binding domain (exon5-8) , the remaining 2 were 
      located in exon 10 and splice site respectively. Patients with TP53 alterations 
      harbored significantly more mutations than whom without alterations (z=-2.418, 
      P=0.016) . The median age of patients with TP53 alterations was higher than their 
      counterparts[60 (21-78) years old vs 52 (14-83) years old, z=-2.188, P=0.029]. 
      TP53 alterations correlated with complex karyotype and International prognostic 
      scoring system intermediate-2/high significantly (P<0.001) . Median overall 
      survival of patients with TP53 alterations was shorter than the others[13 (95%CI 
      7.57-18.43) months vs not reached, chi(2)=12.342, P<0.001], while the significance 
      was lost during complex karyotype adjusted analysis in multivariable model. 
      Conclusion: TP53 mutation was more common than deletion in MDS patients. The 
      majority of mutations were located in the DNA binding domain. TP53 alterations 
      were strongly associated with complex karyotype and always coexisted with other 
      gene mutations. TP53 alteration was no longer an independent prognostic factor 
      when complex karyotype were occurred in MDS.
FAU - Huang, H J
AU  - Huang HJ
AD  - Institute of Hematology and Blood Diseases Hospital CAMS & PUMC, The State Key 
      Laboratory of Experimental Hematology, Tianjin 300020, China.
FAU - Shi, Z X
AU  - Shi ZX
FAU - Li, B
AU  - Li B
FAU - Qin, T J
AU  - Qin TJ
FAU - Xu, Z F
AU  - Xu ZF
FAU - Zhang, H L
AU  - Zhang HL
FAU - Fang, L W
AU  - Fang LW
FAU - Hu, N B
AU  - Hu NB
FAU - Pan, L J
AU  - Pan LJ
FAU - Qu, S Q
AU  - Qu SQ
FAU - Liu, D
AU  - Liu D
FAU - Cai, Y N
AU  - Cai YN
FAU - Zhang, Y D
AU  - Zhang YD
FAU - Xiao, Z J
AU  - Xiao ZJ
LA  - chi
GR  - 81870104, 81530008, 81470297, 81770129/National Natural Science Foundation of 
      China/
GR  - 18JCZDJC34900/Tianjin Key Natural Science Funds/
GR  - 2016-I2M-1-001/CAMS Initiative Fund for Medical Sciences/
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Genes, p53
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Mutation
MH  - *Myelodysplastic Syndromes/genetics
MH  - Prognosis
MH  - Tumor Suppressor Protein p53
MH  - Young Adult
PMC - PMC7342541
OTO - NOTNLM
OT  - Deletion
OT  - Mutation
OT  - Myelodysplastic syndromes
OT  - Prognosis
OT  - TP53 gene
EDAT- 2019/04/02 06:00
MHDA- 2019/04/11 06:00
PMCR- 2019/03/01
CRDT- 2019/04/01 06:00
PHST- 2019/04/01 06:00 [entrez]
PHST- 2019/04/02 06:00 [pubmed]
PHST- 2019/04/11 06:00 [medline]
PHST- 2019/03/01 00:00 [pmc-release]
AID - cjh-40-03-215 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2019.03.010 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):215-221. doi: 
      10.3760/cma.j.issn.0253-2727.2019.03.010.